Now showing items 1-2 of 2

    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07-20)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. 

      Miller, RE; Brough, R; Bajrami, I; Williamson, CT; McDade, S; Campbell, J; Kigozi, A; Rafiq, R; Pemberton, H; Natrajan, R; Joel, J; Astley, H; Mahoney, C; Moore, JD; Torrance, C; Gordan, JD; Webber, JT; Levin, RS; Shokat, KM; Bandyopadhyay, S; Lord, CJ; Ashworth, A (2016-07)
      New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based ...